drugset / Trial / NCT07696520

Bepirovirsen Liver Biopsy Study

NCT07696520

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Bepirovirsen Liver Biopsy study is a single centre open label phase II study to examine the antiviral and immunological effects of bepirovirsen in CHB patients both treated and untreated with HBsAg\<1000 IU/ml

Timeline

Start
2026-07-01
Primary completion
2027-12-30
Completion
2028-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Bepirovirsen Antisense oligonucleotide